## Long-Term Complications and Health Risks in PCOD ### Ovarian Cancer Risk: The Exception **Key Point:** While PCOD is associated with *increased endometrial cancer risk*, the association with **ovarian cancer is NOT significantly elevated** and remains controversial. This is a common misconception in clinical practice. **High-Yield:** The increased endometrial cancer risk in PCOD is well-established because: - Chronic anovulation → unopposed oestrogen stimulation - Lack of progesterone-mediated endometrial protection - Increased risk of endometrial hyperplasia (especially atypical hyperplasia) - Relative risk of endometrial cancer: 2–3 fold higher However, ovarian cancer risk in PCOD remains **debated and not conclusively elevated** in large epidemiological studies. ### Established PCOD Complications | Complication | Mechanism | Risk Elevation | |--------------|-----------|----------------| | **Endometrial hyperplasia/cancer** | Unopposed oestrogen, anovulation | 2–3 fold ↑ | | **Metabolic syndrome** | Insulin resistance, dyslipidemia, hypertension | 3–4 fold ↑ | | **Cardiovascular disease** | Dyslipidemia, hypertension, inflammation, insulin resistance | Increased risk | | **Type 2 diabetes** | Insulin resistance | 5–10 fold ↑ | | **Sleep apnoea (OSA)** | Obesity, androgen excess, airway remodelling | Significantly ↑ in obese PCOD | | **Ovarian cancer** | Unclear; not consistently elevated | **NOT established** | **Clinical Pearl:** Endometrial protection in PCOD is achieved through: 1. Regular menstrual cycles (ovulation induction) 2. Progestin therapy (medroxyprogesterone, norethisterone) 3. Combined oral contraceptives (if not contraindicated) 4. Metformin (improves insulin sensitivity, may reduce hyperplasia risk) **Warning:** Do not counsel PCOD patients about significantly increased ovarian cancer risk — this is not supported by robust evidence and may cause unnecessary anxiety.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.